Among 47 patients with any of several forms of idiopathic inflammatory myositis (IIM) who took efgartigimod (Vyvgart Hytrulo) ...

In a case study of its so-called “drug of the year,” Trinity noted that argenx was able to successfully secure market-leader status for Vyvgart soon after its launch thanks to its “safer ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...

But, having made a second-generation molecule its lead candidate ... Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart Despite claiming the high dose “breaks ...

WASHINGTON -- A drug in advanced development ... the FDA approved efgartigimod (Vyvgart) to treat generalized myasthenia ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

The campaign was launched less than a month after the Food and Drug Administration approved the Vyvgart Hytrulo prefilled syringe as a self-injection treatment for adults diagnosed with either ...

WEDNESDAY, April 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the ...

The Food and Drug Administration (FDA) has approved a prefilled syringe formulation of Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...

75% of gMG patients on Vyvgart showed sustained MG-ADL improvements over 126 weeks. Vyvgart Hytrulo improved functional and QoL scores in gMG and CIDP with no rise in infections over nine ...